MSB MoU for Confirmatory Trial for GI Bleeding in LVAD Patients 27/03/19 PRICE SENSITIVE Share MSB MSB Licensee Files For Skin Disease Marketing Approval 25/03/19 PRICE SENSITIVE Share MSB Mesoblast Provides Half Year Results and Corporate Update 21/02/19 PRICE SENSITIVE Share MSB Half Year Report and Accounts (including Appendix 4D) 21/02/19 PRICE SENSITIVE Share MSB Appendix 4C - quarterly 31/01/19 PRICE SENSITIVE Share MSB MSB Draws US$15 Million From Existing Facility 14/01/19 PRICE SENSITIVE Share MSB P3 Trial of MSB's Cell Therapy in CHF Completes Recruitment 07/01/19 PRICE SENSITIVE Share MSB Response to ASX query 05/12/18 PRICE SENSITIVE Share MSB MSB Provides Q1 Financial Results and Operational Highlights 16/11/18 PRICE SENSITIVE Share MSB First Quarter Financial Results on Form 6-K 16/11/18 PRICE SENSITIVE Share MSB LVAD Results Webcast Presentation 13/11/18 PRICE SENSITIVE Share MSB LVAD Trial Results Provide Potential Regulatory Pathway 12/11/18 PRICE SENSITIVE Share MSB Pause in Trading 12/11/18 PRICE SENSITIVE Share MSB Appendix 4C - quarterly 31/10/18 PRICE SENSITIVE Share MSB MSB Expands Partnership With JCR For Skin Disease 24/10/18 PRICE SENSITIVE Share MSB Completion of Tasly Transaction, and Appendix 3B 12/10/18 PRICE SENSITIVE Share MSB Day 180 Survival Outcomes In aGvHD Phase 3 Trial 20/09/18 PRICE SENSITIVE Share MSB Tasly Receives Approvals For Transaction With MSB 17/09/18 PRICE SENSITIVE Share MSB Mesoblast Reports on Annual and Fourth Quarter Results 30/08/18 PRICE SENSITIVE Share MSB Preliminary Final Report including Appendix 4E 30/08/18 PRICE SENSITIVE Share MSB UPDATE ON TASLY TRANSACTION 29/08/18 PRICE SENSITIVE Share MSB Appendix 4C - quarterly 31/07/18 PRICE SENSITIVE Share MSB MSB Enters Into Cardiovascular Alliance For China With Tasly 17/07/18 PRICE SENSITIVE download Created with Sketch. 80.49KB Share MSB MSB Enters Into US$50M Financing With NovaQuest Capital 02/07/18 PRICE SENSITIVE download Created with Sketch. 80.37KB Share MSB Key Day 100 Survival Results In P3 GvHD Trial 21/06/18 PRICE SENSITIVE download Created with Sketch. 76.22KB Share MSB Third Quarter Financial Results on Form 6-K 31/05/18 PRICE SENSITIVE download Created with Sketch. 515.82KB Share MSB Partnership For Allogeneic Cell-based Cancer Immunotherapies 29/05/18 PRICE SENSITIVE download Created with Sketch. 77.36KB Share MSB Appendix 4C - quarterly 30/04/18 PRICE SENSITIVE Share MSB MSB Enters Into $75 Million Non-Dilutive Credit Facility 07/03/18 PRICE SENSITIVE Share MSB Half Year Report and Accounts (including Appendix 4D) 28/02/18 PRICE SENSITIVE Share MSB GVHD Day 28 Results Presentation 23/02/18 PRICE SENSITIVE Share MSB Primary Endpoint Successfully Achieved in MSB P3 GVHD Trial 22/02/18 PRICE SENSITIVE Share MSB Appendix 4C - quarterly 31/01/18 PRICE SENSITIVE Share MSB Appendix 3B with prospectus 19/01/18 PRICE SENSITIVE Share MSB Mesoblast Receives RMAT For LVAD Heart Failure Patients 21/12/17 PRICE SENSITIVE Share MSB Mesoblast's P3 GVHD Trial Completes Enrollment 20/12/17 PRICE SENSITIVE Share MSB Mesoblast Grants TiGenix License For Treatment of Fistulae 15/12/17 PRICE SENSITIVE Share MSB MSB Named Global Technology Leader In Cell Therapy Industry 08/12/17 PRICE SENSITIVE Share MSB Response to ASX Aware Letter Query 17/11/17 PRICE SENSITIVE Share MSB Mesoblast Provides Corporate Update and Q1 Financial Results 15/11/17 PRICE SENSITIVE Share MSB First Quarter Results On Form 6K 15/11/17 PRICE SENSITIVE Share MSB RA Phase 2 Trial Results Presented At ACR Annual Meeting 13/11/17 PRICE SENSITIVE Share MSB Appendix 4C - quarterly 31/10/17 PRICE SENSITIVE Share MSB End-Stage Heart Failure Trial Completes Enrollment 28/09/17 PRICE SENSITIVE Share MSB Mesoblast Corporate Updates at Healthcare Conferences 25/09/17 PRICE SENSITIVE Share MSB Retail Entitlement Offer 01/09/17 PRICE SENSITIVE Share MSB Mesoblast Reports on Annual and Fourth Quarter Results 30/08/17 PRICE SENSITIVE Share MSB Preliminary Final Report including Appendix 4E 30/08/17 PRICE SENSITIVE Share MSB Underwritten A$50.7M Raise Closes Institutional Allocation 29/08/17 PRICE SENSITIVE Share MSB Fully Underwritten A$50.7 Million Entitlement Offer 25/08/17 PRICE SENSITIVE Share MSB Trading Halt 25/08/17 PRICE SENSITIVE Share MSB Potential For Accelerated Market Entry In Advanced CHF 23/08/17 PRICE SENSITIVE Share MSB Positive Results of MSB Therapy in Osteoarthritis Published 16/08/17 PRICE SENSITIVE Share MSB Appendix 4C - quarterly 31/07/17 PRICE SENSITIVE Share MSB Mesoblast RA Results Presented At EULAR Congress 22/06/17 PRICE SENSITIVE Share MSB MSB Provides Q3 Operational Highlights and Financial Results 25/05/17 PRICE SENSITIVE Share MSB Third Quarter Financial Results On Form 6-K 25/05/17 PRICE SENSITIVE Share MSB Appendix 4C - quarterly 28/04/17 PRICE SENSITIVE Share MSB Successful Interim Analysis in Phase 3 Heart Failure Trial 10/04/17 PRICE SENSITIVE Share MSB Mesoblast Receives A$3.7m From Aus Govt For R&D 06/04/17 PRICE SENSITIVE Share MSB FDA Clears Heart Disease Trial At Boston Childrens Hospital 04/04/17 PRICE SENSITIVE Share MSB Process Initiated For CHF P3 Interim Analysis 31/03/17 PRICE SENSITIVE Share MSB Mesoblast Raises US$40 Million 27/03/17 PRICE SENSITIVE Share MSB Durable Three Year Outcomes in Disc Disease 15/03/17 PRICE SENSITIVE Share MSB FDA Grants Mesoblast Fast Track Designation For GVHD 07/03/17 PRICE SENSITIVE Share MSB Half Year Report and Accounts (including Appendix 4D) 27/02/17 PRICE SENSITIVE Share MSB Positive Nine Month RA Results For Mesoblast Cell Therapy 16/02/17 PRICE SENSITIVE Share MSB Published Results Show MSB Cells Effective In RA Model 13/02/17 PRICE SENSITIVE Share MSB Appendix 4C - quarterly 31/01/17 PRICE SENSITIVE Share MSB Mesoblast Director Recognized For Cardiovascular Leadership 31/01/17 PRICE SENSITIVE Share MSB Mesoblast And Mallinckrodt Enter Into Agreement 23/12/16 PRICE SENSITIVE Share MSB MD Anderson and NIH Fund Trial Using Mesoblast Technologies 06/12/16 PRICE SENSITIVE Share MSB Mesoblast Provides Corporate Update and Q1 Financial Results 15/11/16 PRICE SENSITIVE Share MSB First Quarter Results On Form 6K 15/11/16 PRICE SENSITIVE Share MSB Successful Interim Futility Analysis In P3 Trial for GVHD 14/11/16 PRICE SENSITIVE Share MSB Appendix 4C - quarterly-MSB.AX 31/10/16 PRICE SENSITIVE Share MSB MSB Japan Strategy Highlighted At Business Council Meeting-MSB.AX 12/10/16 PRICE SENSITIVE Share MSB Mesoblast Phase 2 Diabetic Kidney Disease Results Published-MSB.AX 06/10/16 PRICE SENSITIVE Share MSB Preliminary Final Report (Including Appendix 4E)-MSB.AX 28/08/16 PRICE SENSITIVE Share MSB Mesoblast Reports on Annual and Fourth Quarter Results-MSB.AX 28/08/16 PRICE SENSITIVE Share MSB Mesoblast Reports on Annual and Fourth Quarter Results-MSB.AX 25/08/16 PRICE SENSITIVE Share MSB Preliminary Final Report (Including Appendix 4E)-MSB.AX 25/08/16 PRICE SENSITIVE Share MSB MSB Strengthens US Patent Portfolio For Rheumatic Diseases-MSB.AX 17/08/16 PRICE SENSITIVE Share MSB Mesoblast P2 Results Show Dose-Related Improvements In RA-MSB.AX 09/08/16 PRICE SENSITIVE Share MSB MSB Back Pain Results Presented, Receive Best Science Award-MSB.AX 01/08/16 PRICE SENSITIVE Share MSB Appendix 4C - quarterly-MSB.AX 29/07/16 PRICE SENSITIVE Share MSB Update on Heart Failure Trial and Funding of Operations-MSB.AX 01/07/16 PRICE SENSITIVE Share MSB Reinstatement to Official Quotation-MSB.AX 14/06/16 PRICE SENSITIVE Share MSB Update on Global Heart Failure Program-MSB.AX 14/06/16 PRICE SENSITIVE Share MSB Suspension from Official Quotation-MSB.AX 03/06/16 PRICE SENSITIVE Share MSB Trading Halt-MSB.AX 01/06/16 PRICE SENSITIVE Share MSB Mesoblast Receives $6.2m From Aus Govt For R&D-MSB.AX 20/05/16 PRICE SENSITIVE Share MSB Mesoblast Provides Q3 Financial Results and Corporate Update-MSB.AX 10/05/16 PRICE SENSITIVE Share MSB Third Quarter Financial Results On Form 6-K-MSB.AX 10/05/16 PRICE SENSITIVE Share MSB Appendix 4C - quarterly-MSB.AX 28/04/16 PRICE SENSITIVE Share MSB Mesoblast Cells Show Disease Modifying Effects on Knee OA 01/04/16 PRICE SENSITIVE Share MSB Key US Patent Granted For Treatment Of Rheumatoid Arthritis 24/03/16 PRICE SENSITIVE Share MSB GVHD Product Launched In Japan 24/02/16 PRICE SENSITIVE Share MSB Increased Survival Using MSB Cells In Children With aGVHD 22/02/16 PRICE SENSITIVE Share MSB Half Yearly Report and Accounts (including Appendix 4D) 17/02/16 PRICE SENSITIVE Share
(20min delay)
